GOF Mutant p53 in Cancers: A Therapeutic Challenge
<i>TP53</i> is mutated in the majority of human cancers. Mutations can lead to loss of p53 expression or expression of mutant versions of the p53 protein. These mutant p53 proteins have oncogenic potential. They can inhibit any remaining WTp53 in a dominant negative manner, or they can a...
Main Authors: | Lobsang Dolma, Patricia A. J. Muller |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-10-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/20/5091 |
Similar Items
-
Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target
by: Ramona Schulz-Heddergott, et al.
Published: (2018-06-01) -
Gain of Function (GOF) Mutant p53 in Cancer—Current Therapeutic Approaches
by: Katarzyna A. Roszkowska, et al.
Published: (2022-10-01) -
Editorial: Advances in wild type and mutant p53 research in cancer
by: Olga N. Hernández-de la Cruz, et al.
Published: (2022-11-01) -
Cancer Stemness: p53 at the Wheel
by: Dishari Ghatak, et al.
Published: (2021-01-01) -
Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer
by: Shengliang Zhang, et al.
Published: (2022-04-01)